| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H28N4O2 |
| Molar mass | 404.514 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PX-3 (also known asAPP-CHMINACA) is anindazole-basedsynthetic cannabinoid. It is a potentagonist of theCB1 receptor with a binding affinity ofKi = 47.6 nM and was originally developed byPfizer in 2009 as ananalgesic medication.[1][2][3][4]
The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds,PX-1 (5F-APP-PICA, SRF-30),PX-2 (5F-APP-PINACA, FU-PX) andAPP-FUBINACA were reported by theEMCDDA in late 2014.[5][6]
Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.[7]
Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |